|
|
|
|
|
It was a pleasure seeing many of you at the AAN Annual Meeting — what a rewarding experience to connect and
engage with so many dedicated professionals in the epilepsy community. We truly valued the opportunity to exchange
insights, share ideas, and deepen our collective commitment to improving care for people living with epilepsy.
|
|
At UCB, we are proud of our rich heritage in epilepsy, with over 30 years of experience in the research and
development of antiseizure medications. Our long-term commitment to this field continues to drive our e orts to
address unmet medical needs and advance understanding of the condition.
|
|
We remain inspired by patients and driven by science, and we are honored to work alongside world-leading clinicians,
researchers, and partners who share our vision. We look forward to continuing the conversation and collaborating to
shape the future of epilepsy care.
|
|
|
Earlier Identification and Treatment of Patients with a Developmental
and Epileptic Encephalopathy (DEE): Taking a Close Look at
Lennox-Gastaut Syndrome (LGS)
|
|
Presented by
|
Heidi Henninger, MD, FAAN
|
Michael Chez, MD, FAAN, FAES
|
David Burdette, MD, FACNS
|
|
|
|
|
This engaging and thought-provoking event featured a dynamic panel of leading epileptologists who explored
the nuances of diagnosing Lennox-Gastaut syndrome (LGS) in clinical practice. The discussion highlighted red
flags for early identification, critical referral pathways, and the evolving treatment landscape. Through insightful
dialogue, the panel emphasized the profound burden of LGS and the far-reaching consequences of delayed
diagnosis—underscoring the urgent need for awareness, timely intervention, and compassionate care in managing this condition.
|
| |
Rethinking Seizure Emergencies: Expert Perspectives
on a New Paradigm
|
|
Presented by
|
Kamil Detyniecki, MD
|
Sheryl Haut, MD
|
|
|
|
|
This dynamic Industry Therapeutic Update showcased leading experts who explored the latest breakthroughs and
evolving strategies in the management of seizure emergencies. Discussions centered around innovative paradigms
for Rapid and Early Seizure Termination (REST) and Acute Cluster Termination (ACT)—marking a shift toward more
proactive, timely intervention. Through cutting-edge insights and clinical perspectives, attendees gained a deeper
understanding of how these emerging approaches could reshape the standard of care for patients facing acute
seizure episodes.
|
|
|
|
|
|
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the
views expressed here in are those of the presenting corporate entity and not of the AAN. These programs are not an offcial part of the 2025 AAN
Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label
medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
|
| |
|
©2025 UCB, Inc., Smyrna, GA 30080. All rights reserved.
US-FA-2500194
|
| If you no longer wish to receive emails from us, click here to unsubscribe. |
|
|
